Clinical Trial

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Study acronym: EVIDENT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-10.
Trial Details
NCT Number NCT05725200
Lead Sponsor Oslo University Hospital
Conditions Metastatic Colorectal Cancer
Enrollment 40 participants
Start Date 2022-09-27
Primary Completion 2038-12-31 (estimated)
Study Completion 2040-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-02-21